scholarly journals Female lung cancer mortality and long-term exposure to particulate matter in Italy

2016 ◽  
pp. ckw203 ◽  
Author(s):  
Raffaella Uccelli ◽  
Marina Mastrantonio ◽  
Pierluigi Altavista ◽  
Emanuela Caiaffa ◽  
Giorgio Cattani ◽  
...  
2016 ◽  
Vol 2016 (1) ◽  
Author(s):  
Raffaella Uccelli ◽  
Marina Mastrantonio ◽  
Pierluigi Altavista ◽  
Emanuela Caiaffa ◽  
Giorgio Cattani ◽  
...  

2017 ◽  
Vol 186 (8) ◽  
pp. 961-969 ◽  
Author(s):  
Vivian C Pun ◽  
Fatemeh Kazemiparkouhi ◽  
Justin Manjourides ◽  
Helen H Suh

Abstract The impact of chronic exposure to fine particulate matter (particulate matter with an aerodynamic diameter less than or equal to 2.5 μm (PM2.5)) on respiratory disease and lung cancer mortality is poorly understood. In a cohort of 18.9 million Medicare beneficiaries (4.2 million deaths) living across the conterminous United States between 2000 and 2008, we examined the association between chronic PM2.5 exposure and cause-specific mortality. We evaluated confounding through adjustment for neighborhood behavioral covariates and decomposition of PM2.5 into 2 spatiotemporal scales. We found significantly positive associations of 12-month moving average PM2.5 exposures (per 10-μg/m3 increase) with respiratory, chronic obstructive pulmonary disease, and pneumonia mortality, with risk ratios ranging from 1.10 to 1.24. We also found significant PM2.5-associated elevated risks for cardiovascular and lung cancer mortality. Risk ratios generally increased with longer moving averages; for example, an elevation in 60-month moving average PM2.5 exposures was linked to 1.33 times the lung cancer mortality risk (95% confidence interval: 1.24, 1.40), as compared with 1.13 (95% confidence interval: 1.11, 1.15) for 12-month moving average exposures. Observed associations were robust in multivariable models, although evidence of unmeasured confounding remained. In this large cohort of US elderly, we provide important new evidence that long-term PM2.5 exposure is significantly related to increased mortality from respiratory disease, lung cancer, and cardiovascular disease.


2020 ◽  
Vol 738 ◽  
pp. 140195 ◽  
Author(s):  
Ning Wang ◽  
Kerrie Mengersen ◽  
Shilu Tong ◽  
Michael Kimlin ◽  
Maigeng Zhou ◽  
...  

Epidemiology ◽  
2005 ◽  
Vol 16 (5) ◽  
pp. S79 ◽  
Author(s):  
C Yap ◽  
I Beverland ◽  
R M. Agius ◽  
C Robertson ◽  
D J. Hole ◽  
...  

2011 ◽  
Vol 2011 (1) ◽  
Author(s):  
G. Thurston ◽  
R.T. Burnett ◽  
D. Krewski ◽  
M. Turner ◽  
Y. Shi ◽  
...  

2014 ◽  
Vol 180 (12) ◽  
pp. 1145-1149 ◽  
Author(s):  
Michelle C. Turner ◽  
Aaron Cohen ◽  
Michael Jerrett ◽  
Susan M. Gapstur ◽  
W. Ryan Diver ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Poul Suadicani ◽  
Hans Ole Hein ◽  
Finn Gyntelberg

Inflammation and genetic susceptibility influence the risk of lung cancer. During recent years, the role of complement as a part of the humoral response has advanced from being considered complementary to being regarded as a central element in innate immunity. C3 complement allotypes F and S have been associated with a number of inflammatory diseases. The C3F allele frequency is approximately 20% in Caucasian populations and the C3S approximately 80%, resulting in the three predominant genotypes FF (4%), FS (32%), and SS (64%). To our knowledge, no studies have investigated if different C3 allotypes or genotypes predict the risk of lung cancer. We tested in a long-term followup of 3,197 men aged 53 to 74 years the hypothesis that risk of lung cancer would depend on C3 complement genotypes. During 16 years, 160 subjects (5.0%) died from lung cancer, 68 men (6.1%) among complement C3 genotypes FS/FF, and 92 men (4.4%) among genotype SS; age-adjusted hazard ratio with 95%CI (HR) was 1.42 (1.04–1.94) and strongest, 2.71 (1.34–5.45), among the oldest fifth. C3 complement genotype variants were significantly associated with lung cancer mortality.


Sign in / Sign up

Export Citation Format

Share Document